|
| 1. |
Identify genomic abnormalities in cancers using deep nucleotide sequencing, SNP Chip analysis and shRNA library analysis. |
| 2. |
Determine the biologic significance of these genomic abnormalities and to potentially identify therapeutic agents targeted against the products of these alterations. |
|
| 1. |
Exome sequencing to determine novel mutations in leukemias, nasopharyngeal tumors, liposarcomas, pancreatic cancers, breast cancers and non-small cell lung cancers. |
| 2. |
Discover Pathways Whose Inhibition Can Synergize with a PARP Inhibitor in Triple-Negative Breast Cancer |
| 3. |
Identification of drug response biomarkers in pancreatic cancer by synthetic lethality. |
|
